CL2024000063A1 - Biomarcadores para el tratamiento de la enfermedad de alzheimer - Google Patents
Biomarcadores para el tratamiento de la enfermedad de alzheimerInfo
- Publication number
- CL2024000063A1 CL2024000063A1 CL2024000063A CL2024000063A CL2024000063A1 CL 2024000063 A1 CL2024000063 A1 CL 2024000063A1 CL 2024000063 A CL2024000063 A CL 2024000063A CL 2024000063 A CL2024000063 A CL 2024000063A CL 2024000063 A1 CL2024000063 A1 CL 2024000063A1
- Authority
- CL
- Chile
- Prior art keywords
- alzheimer
- disease
- biomarkers
- treatment
- suspected
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4709—Amyloid plaque core protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Neurosurgery (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Neurology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163220434P | 2021-07-09 | 2021-07-09 | |
| US202163203444P | 2021-07-22 | 2021-07-22 | |
| US202163263255P | 2021-10-29 | 2021-10-29 | |
| US202163263928P | 2021-11-11 | 2021-11-11 | |
| US202163264551P | 2021-11-24 | 2021-11-24 | |
| US202263306028P | 2022-02-02 | 2022-02-02 | |
| US202263269372P | 2022-03-15 | 2022-03-15 | |
| US202263364618P | 2022-05-12 | 2022-05-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2024000063A1 true CL2024000063A1 (es) | 2024-08-02 |
Family
ID=83232761
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2024000063A CL2024000063A1 (es) | 2021-07-09 | 2024-01-08 | Biomarcadores para el tratamiento de la enfermedad de alzheimer |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250163135A1 (https=) |
| EP (1) | EP4367516A1 (https=) |
| JP (1) | JP2024525559A (https=) |
| KR (1) | KR20240033017A (https=) |
| AU (1) | AU2022307687A1 (https=) |
| CA (1) | CA3225302A1 (https=) |
| CL (1) | CL2024000063A1 (https=) |
| IL (1) | IL309468A (https=) |
| MX (1) | MX2023015183A (https=) |
| TW (1) | TW202317192A (https=) |
| WO (1) | WO2023283650A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024064897A1 (en) | 2022-09-23 | 2024-03-28 | Eisai R&D Management Co., Ltd. | Methods of reducing neurodegeneration associated with neurodegenerative diseases |
| WO2025019457A1 (en) * | 2023-07-15 | 2025-01-23 | Eisai R&D Management Co., Ltd. | Antimicrobial peptides |
| WO2025260029A1 (en) | 2024-06-14 | 2025-12-18 | Eisai R&D Management Co., Ltd. | Method for quantifying amyloid beta protofibril |
| CN118777453B (zh) * | 2024-06-25 | 2025-04-08 | 上海交通大学医学院附属瑞金医院 | 一种基于液相色谱-串联质谱定量分析血液中仑卡奈单抗浓度的方法 |
| WO2026015877A1 (en) | 2024-07-12 | 2026-01-15 | Eisai R&D Management Co., Ltd. | Fluid biomarker |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2414772C (en) | 2000-07-07 | 2011-06-28 | Jan Naslund | Prevention and treatment of alzheimer's disease |
| SE0401601D0 (sv) | 2004-06-21 | 2004-06-21 | Bioarctic Neuroscience Ab | Protofibril specific antibodies and uses thereof |
| RU2429244C2 (ru) | 2006-03-23 | 2011-09-20 | Байоарктик Ньюросайенс Аб | Улучшенные селективные в отношении протофибрилл антитела и их применение |
| LT2448968T (lt) | 2009-06-29 | 2021-05-10 | Bioarctic Ab | Antikūnai, atpažįstantys n gale sutrumpintas amiloido protofibriles/oligomerus |
| JP5894939B2 (ja) | 2010-02-26 | 2016-03-30 | バイオアークティック ニューロサイエンス アーベー | プロトフィブリル結合抗体ならびにパーキンソン病、レビー小体型認知症および他のα−シヌクレイノパチーの治療および診断方法におけるこれらの使用 |
| WO2016005466A2 (en) | 2014-07-10 | 2016-01-14 | Bioarctic Neuroscience Ab | IMPROVED Aß PROTOFIBRIL BINDING ANTIBODIES |
| AU2018352308B2 (en) | 2017-10-16 | 2025-06-05 | Eisai R&D Management Co., Ltd. | Anti-tau antibodies and uses thereof |
| RS67249B1 (sr) | 2020-03-20 | 2025-10-31 | Eisai R&D Man Co Ltd | Formulacije antitela visoke koncentracije protiv protofibrila amiloid beta peptida i metode njihove upotrebe |
| IL296992A (en) * | 2020-04-03 | 2022-12-01 | Alector Llc | Methods for using anti-trem2 antibodies |
| TWI843040B (zh) * | 2021-01-11 | 2024-05-21 | 美商美國禮來大藥廠 | 抗N3pGlu類澱粉β抗體及其用途 |
-
2022
- 2022-07-08 AU AU2022307687A patent/AU2022307687A1/en active Pending
- 2022-07-08 WO PCT/US2022/073576 patent/WO2023283650A1/en not_active Ceased
- 2022-07-08 EP EP22765973.7A patent/EP4367516A1/en active Pending
- 2022-07-08 CA CA3225302A patent/CA3225302A1/en active Pending
- 2022-07-08 JP JP2024500220A patent/JP2024525559A/ja active Pending
- 2022-07-08 TW TW111125802A patent/TW202317192A/zh unknown
- 2022-07-08 KR KR1020247004758A patent/KR20240033017A/ko active Pending
- 2022-07-08 IL IL309468A patent/IL309468A/en unknown
- 2022-07-08 US US18/577,174 patent/US20250163135A1/en active Pending
- 2022-07-08 MX MX2023015183A patent/MX2023015183A/es unknown
-
2024
- 2024-01-08 CL CL2024000063A patent/CL2024000063A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3225302A1 (en) | 2023-01-12 |
| JP2024525559A (ja) | 2024-07-12 |
| MX2023015183A (es) | 2024-03-14 |
| AU2022307687A1 (en) | 2024-01-04 |
| KR20240033017A (ko) | 2024-03-12 |
| EP4367516A1 (en) | 2024-05-15 |
| US20250163135A1 (en) | 2025-05-22 |
| TW202317192A (zh) | 2023-05-01 |
| IL309468A (en) | 2024-02-01 |
| WO2023283650A1 (en) | 2023-01-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2024000063A1 (es) | Biomarcadores para el tratamiento de la enfermedad de alzheimer | |
| CL2024002309A1 (es) | Métodos de tratamiento usando nivel de p-tau181. | |
| CL2020000343A1 (es) | Métodos y materiales para evaluar y tratar el cáncer. | |
| BRPI0720035A2 (pt) | métodos para tratar um paciente tendo uma doença ou distúrbio, para tratar um paciente com doença autoimune, para neutralizar um perfil de expressão do marcador pd indutível por ifn do tipo 1 ou ifnalfa em um paciente, para monitorar ou prognosticar progressão de doença autoimune de um paciente, para monitorar a progressão da doença de um paciente que recebe o tratamento com um agente terapêutico que liga-se a e modula a atividade de ifnalfa, para identificar um paciente como um candidato para um agente terapêutico que liga-se a e modula a atividade de ifnalfa, para diagnosticar um paciente como tendo um distùrbio associado com níveis aumentados de ifnalfa, para identificar um terapêutico candidato para o tratamento de distùrbios mediados por ifnalfa e para detectar atividade de ifn em uma amostra, conjunto de sondas, e, kit | |
| MX2025005880A (es) | Metodos de tratamiento que usan un nivel de tomografia de emision de positrones (pet) de tau | |
| EA202192260A1 (ru) | Биомаркеры циклин-зависимой киназы 2 и их применение | |
| WO2015157407A8 (en) | Small molecule biochemical profiling of individual subjects for disease diagnosis and health assessment | |
| CY1118660T1 (el) | Συνθεσεις και μεθοδοι για την θεραπεια διαταραχων ματιων | |
| CY1118566T1 (el) | Διαγνωση με χρηση ιντερφερονης τυπου 1 | |
| MX2020011458A (es) | Metodos de diagnostico y tratamiento basados en fosforilacion de tau especifica del sitio. | |
| Ally et al. | Preserved frontal memorial processing for pictures in patients with mild cognitive impairment | |
| EA200901550A1 (ru) | Способы лечения, диагностирования и выявления ассоциированных с fgf21 нарушений | |
| CR8230A (es) | Sondas para enfermedades en las cuales se acumula amiloide, agentes para tincion del amiloide, farmacos para tratamiento y profilaxis de enfermedades con amiloide acumulado y sondas para diagnostico de ovillos neuro fibrilares yagentes... | |
| BR112014031414A2 (pt) | métodos de detectar doenças ou condições utilizando células doentes circulantes | |
| MX2019009986A (es) | Deteccion temprana de la activacion de celulas gliales en enfermedades neurodegenerativas o neuroinflamatorias. | |
| CL2023001600A1 (es) | Biomarcadores del agonista de trem2 y métodos para su uso | |
| BR112022004326A2 (pt) | Ensaio de base sanguínea para diagnóstico e tratamento com base em fosforilação de tau específica do sítio | |
| BR112022014553A2 (pt) | Métodos para tratamento de sintomas neurológicos associados a doenças do armazenamento lisossômic | |
| MX2024013120A (es) | Analisis del transcriptoma para el tratamiento de la inflamacion | |
| CR20230121A (es) | Tratamiento de la enfermedad de parkinson | |
| FR3060755B1 (fr) | Methode de diagnostic d'une peau presentant des signes de secheresse | |
| MX2018011679A (es) | Biomarcadores de proteopatias y usos de los mismos. | |
| EP3850108A4 (en) | MOLECULAR AND FUNCTIONAL CHARACTERIZATION OF EARLY-STAGE PARKINSON'S DISEASE AND TREATMENTS | |
| EA202192176A1 (ru) | Нарушения, опосредованные интерфероном i типа | |
| WO2023129531A3 (en) | Methods for diagnosing and/or treating alzheimer's disease |